AU2013319737B2 - Improved daptomycin injectable formulation - Google Patents

Improved daptomycin injectable formulation Download PDF

Info

Publication number
AU2013319737B2
AU2013319737B2 AU2013319737A AU2013319737A AU2013319737B2 AU 2013319737 B2 AU2013319737 B2 AU 2013319737B2 AU 2013319737 A AU2013319737 A AU 2013319737A AU 2013319737 A AU2013319737 A AU 2013319737A AU 2013319737 B2 AU2013319737 B2 AU 2013319737B2
Authority
AU
Australia
Prior art keywords
daptomycin
formulation
lyophilized
tocopheryl phosphate
tpm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013319737A
Other languages
English (en)
Other versions
AU2013319737A1 (en
Inventor
Satya Srinivas CHETLAPALLI
Babu JUSTIN
Srirama Sarveswara Rao MANDAVILLI
Sathyanarayan Srinivas MEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of AU2013319737A1 publication Critical patent/AU2013319737A1/en
Priority to AU2018204334A priority Critical patent/AU2018204334A1/en
Assigned to MYLAN LABORATORIES LIMITED reassignment MYLAN LABORATORIES LIMITED Request for Assignment Assignors: AGILA SPECIALTIES PRIVATE LIMITED
Application granted granted Critical
Publication of AU2013319737B2 publication Critical patent/AU2013319737B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013319737A 2012-08-23 2013-08-22 Improved daptomycin injectable formulation Ceased AU2013319737B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018204334A AU2018204334A1 (en) 2012-08-23 2018-06-18 Improved daptomycin injectable formulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2452MU2012 2012-08-23
IN2452/MUM/2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018204334A Division AU2018204334A1 (en) 2012-08-23 2018-06-18 Improved daptomycin injectable formulation

Publications (2)

Publication Number Publication Date
AU2013319737A1 AU2013319737A1 (en) 2015-02-05
AU2013319737B2 true AU2013319737B2 (en) 2018-08-02

Family

ID=54187094

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013319737A Ceased AU2013319737B2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation
AU2018204334A Abandoned AU2018204334A1 (en) 2012-08-23 2018-06-18 Improved daptomycin injectable formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018204334A Abandoned AU2018204334A1 (en) 2012-08-23 2018-06-18 Improved daptomycin injectable formulation

Country Status (12)

Country Link
US (1) US20150216928A1 (enExample)
EP (2) EP3287138A1 (enExample)
JP (1) JP2015526463A (enExample)
AU (2) AU2013319737B2 (enExample)
BR (1) BR112015003198A2 (enExample)
CA (1) CA2881121A1 (enExample)
DK (1) DK2887953T3 (enExample)
ES (1) ES2655215T3 (enExample)
NO (1) NO2887953T3 (enExample)
PT (1) PT2887953T (enExample)
SI (1) SI2887953T1 (enExample)
WO (1) WO2014045296A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4066849T3 (pl) * 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
CN1069320C (zh) * 1995-10-17 2001-08-08 昭和电工株式会社 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
US9168216B2 (en) * 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CN102625697A (zh) * 2009-09-01 2012-08-01 西北大学 使用经寡核苷酸修饰的纳米颗粒作为载体来递送治疗剂
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094814A1 (en) * 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate

Also Published As

Publication number Publication date
PT2887953T (pt) 2018-01-10
AU2013319737A1 (en) 2015-02-05
EP2887953A4 (en) 2016-05-25
EP2887953B1 (en) 2017-10-11
EP3287138A1 (en) 2018-02-28
ES2655215T3 (es) 2018-02-19
JP2015526463A (ja) 2015-09-10
WO2014045296A2 (en) 2014-03-27
DK2887953T3 (en) 2018-01-15
NO2887953T3 (enExample) 2018-03-10
US20150216928A1 (en) 2015-08-06
CA2881121A1 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
EP2887953A2 (en) 2015-07-01
AU2018204334A1 (en) 2018-07-05
BR112015003198A2 (pt) 2017-10-10
SI2887953T1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
AU2018204334A1 (en) Improved daptomycin injectable formulation
CN111603439B (zh) 一种长效依匹哌唑原位相变凝胶注射剂及其制备方法
WO2022129264A1 (en) Aqueous solution
EA033988B1 (ru) Инъецируемые фармацевтические композиции лефамулина
WO2022129263A1 (en) Aqueous solution
US12629337B2 (en) Daptomycin formulation
CN101961311A (zh) 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
CN104721155A (zh) 一种替莫唑胺冻干粉制剂及其制备方法
WO2012013116A1 (zh) 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法
JP2020533318A (ja) ドセタキセル結合体の医薬組成物及び調製方法
CN103330933B (zh) 含有米卡芬净或其盐的药物组合物
JP3956654B2 (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
WO2006105399A1 (en) Methods for administering ixabepilone
CN106176626B (zh) L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物
JP6189437B2 (ja) 注射用抗生物質製剤およびその使用方法
CN103330932B (zh) 一种米卡芬净或其盐的药物组合物
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
TWI426929B (zh) 持續性釋放之含抗生素醫藥組合物、製備法及其應用
RS61582B1 (sr) Poboljšani kit za pripremu injektabilnih rastvora karmustina
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法
CN105982892A (zh) 含抗氧化剂的替莫唑胺药物组合物及其制备方法
NZ613138A (en) Injectable antibiotic formulations and their methods of use
NZ613138B2 (en) Injectable antibiotic formulations and their methods of use
HK1069775B (en) Compositions containing piperacillin and tazobactam useful for injection

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MYLAN LABORATORIES LIMITED

Free format text: FORMER APPLICANT(S): AGILA SPECIALTIES PRIVATE LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired